BMO Capital downgraded Tokai Pharmaceuticals (NASDAQ: TKAI) from Outperform to Market Perform with a price target of $1.70 (from $11.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

BMO Capital Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 10:44 AM Stifel Downgrades Tokai Pharmaceuticals (TKAI) to HoldJuly 26, 2016 9:45 AM Pre-Open Stock Movers 07/26: (EXAS) (CRY) (NFLX) Higher; (TKAI) (CRME) (MSTX) (NDLS) (MBLY) Lower (more...)July 26, 2016 9:32 AM Janney Montgomery Scott Downgrades Tokai Pharmaceuticals (TKAI) to NeutralJuly 26, 2016 8:50 AM Wells Fargo Downgrades Tokai Pharmaceuticals (TKAI) to Market PerformJuly 26, 2016 8:23 AM Tokai Pharma (TKAI) will resume trading at 7:30am ETJuly 26, 2016 7:20 AM Tokai Pharma (TKAI) to Cease ARMOR3-SV Clinical TrialJuly 26, 2016 7:05 AM Tokai Pharmaceuticals Announces Clinical UpdateJuly 26, 2016 7:00 AM Tokai Pharma (TKAI) trading halted with news pendingJuly 26, 2016 6:55 AM